ArticleDiscover oncology2026
Analysis of clinical and histopathological features in concurrent papillary and medullary thyroid carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveConcurrent papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC) is a rare entity. We aimed to investigate the clinicopathological features, treatment, and prognosis of this coexistence.
methodsWe retrospectively studied 23 patients with concurrent PTC and MTC presenting as collision tumors (referred to as PTC/MTC) between 2011 and 2023 at our center.
resultsAmong 197 MTC patients, 23 (11.7%) had PTC/MTC. Preoperative assessments revealed an 88.9% positivity rate for calcitonin and a 54.5% positivity rate for carcinoembryonic antigen. Thyroid ultrasonography showed more than one nodule suspicious of malignancy in 73.9% of the patients and detected nodal metastases in 63.9%. The MTC component had a higher frequency of abundant blood-flow signals than the PTC component (p = 0.009). Fine-needle aspiration cytology (FNAC) diagnosed only one tumor component in 75.0% cases. Among the 23 cases with PTC/MTC, 15 (65.2%) were identified as medullary thyroid microcarcinoma (micro-MTC), 19 cases (82.6%) as papillary thyroid microcarcinoma (micro-PTC). The proportion of micro-MTC in collision tumors was significantly higher than that in all MTC cases (p < 0.001). Further comparison between micro-MTCs in PTC/MTC and those not associated with PTC demonstrated no significant differences in clinicopathological features and prognosis.
conclusionsIn this cohort, PTC/MTC was found in approximately 1 in 10 MTC patients. Multiple suspicious malignant thyroid nodules with abundant blood-flow signals warrant vigilance for concurrent PTC and MTC, even if FNAC detects only one tumor component. Micro-MTC accounts for a high proportion of PTC/MTC cases, and its clinicopathological features are not influenced by the presence of a PTC component.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.